Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia
Spain site opens with two R/R AML subjects enrolled; One treated On track to recruit 45 subjects in 4Q25 for...
Brain
NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults
BOSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for neurological disorders and neuro-oncology,...
Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures
Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in...
NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND
Oversubscribed £50m Series B led by SV Health Investors’ Dementia Discovery Fund, alongside other new investors British Business Bank, M...
ONWARD Medical Receives CE Mark for ARC-EX, Enabling Commercial Launch of Breakthrough Spinal Cord Stimulation System in Europe
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The...
Data published in The New England Journal of Medicine demonstrate RYBREVANT®▼(amivantamab) plus LAZCLUZE®▼ (lazertinib) could re-set survival expectations in first-line EGFR-mutated advanced lung cancer
Chemotherapy-free combination regimen has the potential to usher in new era for first-line treatment, with median overall survival projected to...
RYBREVANT®▼ (amivantamab) plus LAZCLUZE®▼ (lazertinib) reduces acquired resistance versus osimertinib in first-line EGFR-mutated advanced non-small cell lung cancer
New data demonstrate amivantamab combination significantly reduces common EGFR and MET resistance mutations seen with EGFR TKIs1 BEERSE, BELGIUM ,...
PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - September 5, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"),...
Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September
FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused...
24/7 Market News: Kraig Labs Fibers are 5X Stronger Than Steel, Tougher than Kevlar, and Biodegradable
This Isn’t Sci-Fi, it’s Spider Silk!DENVER, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to...
Functional Medicine is Longevity Medicine(TM) Masterclass to Redefine the Future of Healthspan
Free 3-day online event brings together 30+ global leaders to unite functional and longevity medicine with cutting-edge science and clinical...
123Invent Inventor Develops Brain-Computer Interface & Defense System (MHO-628)
PITTSBURGH, Sept. 4, 2025 /PRNewswire/ -- "I wanted to create a wireless, non-invasive brain-computer interface to facilitate direct communication between...
PreveCeutical Announces Arrangement Agreement with BioGene Therapeutics
Vancouver, British Columbia--(Newsfile Corp. - September 4, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) (the "Company" or...
BrainSpec and University of Minnesota Collaborate to Advance Automation in MR Spectroscopy with AutoVOI
The enhancement of virtual biopsy technology automates traditional manual methods of selecting regions of the brain for Magnetic Resonance Spectroscopy...
Hoth Therapeutics Taps Lantern Pharma’s PredictBBB.ai Platform — Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development
NEW YORK, Sept. 4, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced that it...
Hemostemix’s VesCell.Health Launched in Florida
Calgary, Alberta--(Newsfile Corp. - September 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's...
Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease
Novel human preclinical neuronal model for Parkinson’s disease demonstrated CNM-Au8’s ability to improve mitochondrial health, restore cellular metabolism, reduce inflammation,...
Bright Minds Biosciences Announces BMB‑201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG) today announced compelling preclinical results for...
Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference
PRINCETON, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage,...
SeoulTech Scientist Develops Artificial Synapses That Mimic Human Brain Function for Next-Gen AI Chips
The innovative organic materials proposed by Dr. Eunho Lee and his team bring us closer to brain-like computer processors In...